Group 1 - Ariel Focus Fund reported a decline of -0.50% in Q4 2025, underperforming the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81% respectively, but achieved a +20.97% return over the full year [1] - The U.S. market environment in Q4 2025 was characterized by easing inflation, stable corporate earnings, and optimism around accommodative monetary policy, alongside strength in AI and cloud-driven technology stocks [1] - The fund maintained a disciplined, long-term investment approach, selectively adding to positions without making exits during the quarter [1] Group 2 - Johnson & Johnson (NYSE: JNJ) experienced a one-month return of -1.73%, with shares trading between $141.50 and $251.71 over the last 52 weeks, closing at approximately $242.49 on March 30, 2026, with a market capitalization of about $584.38 billion [2] - Johnson & Johnson's performance was bolstered by strong earnings and an increase in full-year revenue guidance, focusing on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision [3] - The company is entering a new era of accelerated growth and innovation, supported by key growth products and a robust pipeline, reaffirming confidence in its long-term prospects [3]

Core Insights - Legend Biotech Corporation (NASDAQ:LEGN) is identified as a high growth healthcare stock with significant investment potential, despite recent price target adjustments by analysts [1][2] Group 1: Financial Performance and Analyst Ratings - RBC Capital reduced its price target for Legend Biotech to $62 from $66 while maintaining an Outperform rating, citing a disconnect between share price and business fundamentals [1] - Morgan Stanley also updated its price target to $49 from $50, reiterating an Overweight rating, and is awaiting further data from ongoing studies [2] Group 2: Company Overview - Legend Biotech is a clinical-stage company focused on developing, discovering, manufacturing, and commercializing novel therapies for oncology and other indications, utilizing advanced cell therapies across various technology platforms [3]

Core Viewpoint - The article emphasizes the importance of investing in defensive stocks amid recent market volatility, highlighting five specific stocks that are well-positioned for stability and growth in uncertain economic conditions [2][4][5]. Group 1: Market Conditions - U.S. stock markets experienced significant volatility in March due to concerns over the sustainability of the AI trade, ongoing geopolitical tensions, rising crude oil and gas prices, inflation expectations, and uncertainty regarding the Federal Reserve's interest rate policy [2]. - The Nasdaq Composite and Dow are in correction territory, trading below 10% from recent highs, while the S&P 500 has recorded its fifth consecutive weekly decline, trading below 8.7% from its recent peak [3]. Group 2: Stock Selection Criteria - Investment in defensive stocks is recommended to safeguard portfolio returns in the near term, focusing on sectors such as utilities, consumer staples, and healthcare [4]. - Stocks selected should be low-beta (beta >0<1) and regularly pay dividends [4]. Group 3: Featured Stocks - **Duke Energy Corp. (DUK)**: Plans to invest $103 billion from 2026-2030 to enhance its grid and expand renewable energy initiatives. DUK has a revenue growth rate of 3.3% and earnings growth rate of 6.3% for the current year, with a dividend yield of 3.28% and a beta of 0.50 [6][10][11]. - **Entergy Corp. (ETR)**: Aims to invest $41 billion from 2026-2029 for infrastructure upgrades and renewable expansion. ETR has a revenue growth rate of 6.8% and earnings growth rate of 12.8% for the current year, with a dividend yield of 2.33% and a beta of 0.64 [12][13]. - **Constellation Brands Inc. (STZ)**: Successfully transitioning to premium brands, with a revenue growth rate of 1.5% and earnings growth rate of 6.5% for the current year, alongside a dividend yield of 2.69% and a beta of 0.44 [14][16]. - **The Coca-Cola Co. (KO)**: Benefits from strong organic revenue growth and effective pricing strategies, with a revenue growth rate of 3.2% and earnings growth rate of 8% for the current year, a dividend yield of 2.80% and a beta of 0.35 [17][19]. - **Johnson & Johnson (JNJ)**: The Innovative Medicine unit shows growth despite exclusivity loss, with a revenue growth rate of 6.6% and earnings growth rate of 7% for the current year, a dividend yield of 2.16% and a beta of 0.34 [20][22].

Core Viewpoint - Johnson & Johnson's Innovative Medicine segment is expected to show growth in Q1 2026, driven by key product sales despite challenges from the loss of exclusivity of Stelara and competitive pressures from biosimilars [1][10]. Sales Performance - The Innovative Medicine unit's sales increased by 4.1% on an organic basis in 2025, even with the loss of exclusivity for Stelara and the negative impact of the Part D redesign [2]. - The segment achieved over $15 billion in sales for three consecutive quarters in 2025, a trend anticipated to continue into Q1 2026 [2]. Key Product Contributions - Growth in Q1 2026 is expected to be supported by increased sales of Darzalex, Tremfya, and Erleada, along with market share gains and expansion [3]. - Newer therapies such as Carvykti, Tecvayli, Talvey, Rybrevant, Lazcluze, Caplyta, and Spravato are also projected to contribute to overall growth [3]. Competitive Landscape - The launch of several biosimilar versions of Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [5]. - Imbruvica sales are expected to decline due to rising competition, and the Part D redesign is anticipated to further affect sales of Stelara, Imbruvica, and Erleada [6]. New Product Developments - Investors are keen on commercialization plans and initial sales figures for newly approved products like Inlexzoh/TAR-200 and Imaavy [7]. - The FDA recently approved Icotyde for treating moderate-to-severe plaque psoriasis, although it will not contribute to Q1 2026 sales [8]. Market Position and Valuation - J&J's shares have outperformed the industry, rising 46.2% over the past year compared to the industry's 10.6% increase [11]. - The company's shares are trading at a forward price/earnings ratio of 20.36, higher than the industry average of 16.99 and above its five-year mean of 15.65 [13]. Earnings Estimates - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, while the estimate for 2027 has increased from $12.33 to $12.44 [15]. - Current estimates for Q1 and Q2 2026 are $2.69 and $2.93 per share, respectively [16].

Industry Overview - The global oncology market is experiencing rapid evolution due to rising cancer incidence, aging populations, and scientific breakthroughs, with the U.S. projected to have approximately 2.1 million new cancer cases and over 626,000 deaths in 2026 [2] - Lifestyle-related risk factors and demographic shifts are driving higher cancer prevalence, leading to long-term growth in oncology-related healthcare spending [2] Treatment Innovations - Innovations in immunotherapy, targeted therapies, and personalized cancer vaccines are expanding treatment options beyond conventional methods [3] - Emerging technologies like genomic sequencing, AI, and machine learning are enhancing biomarker discovery and enabling earlier, more accurate diagnoses [4] Pharmaceutical Industry Response - Major pharmaceutical companies such as Novartis, AstraZeneca, J&J, Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly are investing in oncology pipelines with advanced modalities like antibody-drug conjugates and next-generation immuno-oncology therapies [5] - Smaller biotech firms are crucial in driving innovation, often leading to partnerships and M&A activity [5] Market Resilience - Oncology is considered one of the most resilient and attractive segments of the global healthcare sector for long-term investors, supported by ongoing innovation and favorable reimbursement trends [6] Company Highlights: Johnson & Johnson (J&J) - J&J's oncology segment accounts for approximately 27% of total revenues, with oncology sales rising 20.9% in 2025, driven by strong market growth and key products like Darzalex and Erleada [9] - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $3.0 billion in sales in 2025 and are expected to contribute to a target of $50 billion in oncology sales by 2030 [10][11] - The company is expanding its oncology pipeline through M&A, including the acquisition of Halda Therapeutics [12] Company Highlights: Verastem Oncology - Verastem Oncology focuses on targeting key signaling pathways and received FDA approval for its combination regimen for treating KRAS mutant recurrent low-grade serous ovarian cancer, generating $30.9 million in sales in 2025 [14][15] - The company is also evaluating its therapies in other cancer types and developing new candidates for KRAS G12D mutant solid tumors [16] Company Highlights: Xilio Therapeutics - Xilio Therapeutics has an exclusive license agreement with Gilead for its investigational tumor-activated IL-12 inhibitor and plans to submit an IND application for its bispecific PD-1 / masked IL-2 candidate [17][18] - The company is advancing preclinical T-cell engagers targeting various tumor antigens, with plans for clinical development by 2027 [19]

Core Insights - Johnson & Johnson (J&J) has a robust R&D pipeline focusing on immunology, oncology, and neuroscience, with significant advancements and approvals expected to drive growth through the latter half of the decade [1][10] R&D and Product Approvals - In 2025, J&J received approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis, marking key milestones in its pipeline [1][10] - The FDA approved Icotyde (icotrokinra), an oral treatment for moderate-to-severe plaque psoriasis, co-developed with Protagonist Therapeutics, enhancing J&J's portfolio [2][4] - Inlexzoh is a novel drug-releasing system for bladder cancer, while nipocalimab is being evaluated for various immune-mediated conditions, indicating its potential as a versatile treatment option [3][5] Market Potential and Sales Growth - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $3 billion in sales in 2025, contributing to overall revenue growth [6][10] - The company anticipates that 10 of its new products could achieve peak sales of $5 billion, with expectations for a more significant impact from new products in 2026 compared to 2025 [7][8] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 47.1% over the past year compared to the industry's 9.5% increase [11] - The company's shares are currently trading at a price/earnings ratio of 20.42, higher than the industry average of 16.75, indicating a slightly expensive valuation [12] - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, with a slight increase for 2027 earnings from $12.33 to $12.44 [13][14]

Core Insights - Johnson & Johnson's stock has shown strong performance, remaining above its 50-day and 200-day simple moving averages for over eight months, indicating sustained investor confidence [1] - The stock formed a "golden cross" in July, suggesting a potential for a prolonged bullish trend, supported by improving business performance [1] Sales and Earnings Growth - J&J's share price performance is driven by steady growth in sales and earnings, particularly from the Innovative Medicine and MedTech segments, with an optimistic outlook for 2026 [2] - The Innovative Medicine segment saw a 4.1% organic sales growth in 2025, despite the loss of exclusivity for Stelara, with key drugs like Darzalex, Erleada, and Tremfya contributing significantly [4][5] - The segment achieved over $60 billion in full-year sales in 2025, with 13 brands growing in double digits [5] Pipeline and R&D Investments - J&J invested over $32 billion in R&D and M&A in 2025, including acquisitions that enhance its product portfolio [10] - Significant pipeline advancements were made in 2025, with new product approvals expected to drive growth in 2026 [11][12] - J&J believes that several new products have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, and Imaavy [14] MedTech Segment Performance - The MedTech segment improved sales by 4.3% on an organic basis in 2025, driven by acquisitions and advancements in various product lines [15] - J&J anticipates better growth in the MedTech business in 2026, despite facing challenges in the Chinese market due to government cost containment efforts [16][17] Challenges and Risks - The loss of U.S. patent exclusivity for Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [18][19] - J&J faces over 74,000 lawsuits related to its talc-based products, which could pose significant legal and financial challenges [21][22] Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 46.2% over the past year compared to a 7.5% increase in the industry [23] - The stock is currently trading at a price/earnings ratio of 20.05, higher than the industry average of 16.69, indicating a slightly expensive valuation [27] Future Outlook - The Zacks Consensus Estimate for 2026 earnings has increased, reflecting positive sentiment around J&J's growth prospects [30] - J&J aims to generate around $100 billion in revenues in 2026, with expectations for sales growth in both segments to be higher than in 2025 [34] - Despite facing headwinds, J&J remains confident in navigating challenges and maintaining strong momentum [34][35]

Core Insights - Pfizer is a leading oncology drugmaker with a strong portfolio and pipeline across various cancer types, including breast, genitourinary, thoracic, gastrointestinal, and blood cancers [1] - The company's oncology revenues grew by 8% year over year in 2025, accounting for approximately 27% of total revenues [2] Oncology Pipeline and Development - Key candidates in late-stage development include atirmociclib for metastatic breast cancer and sigvotatug vedotin for metastatic non-small cell lung cancer [3] - A regulatory application for vepdegestrant for ER+/HER2- metastatic breast cancer is under review in the U.S., and sasanlimab for high-risk non-muscle invasive bladder cancer is under review in the EU [3] Clinical Study Results - The FOURLIGHT-1 study showed that atirmociclib combined with fulvestrant met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival [4][5] - Atirmociclib treatment resulted in a 40% reduction in the risk of disease progression or death [5] - The treatment was well tolerated and had a manageable safety profile, particularly in a hard-to-treat patient population [6] Competitive Landscape - Pfizer competes with major players like AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers in the oncology space [9] - AstraZeneca's oncology sales rose 14% in 2025, while Merck's Keytruda generated $31.7 billion in sales, up 7% year over year [11][12] - Johnson & Johnson's oncology sales increased by 20.9% to $25.4 billion, and Bristol-Myers' Opdivo sales rose 8% to $10 billion [13][14] Financial Performance and Valuation - Pfizer's shares have increased by 10.2% year to date, contrasting with a 0.1% decline in the industry [17] - The company is trading at a price/earnings ratio of 9.33, below the industry average of 17.65 and its five-year mean of 10.15 [18] - The Zacks Consensus Estimate for 2026 earnings has slightly declined from $2.99 to $2.97 per share [19]

Investment Rating - The investment rating for the company is "Buy" [3][10]. Core Insights - The report indicates that 2026 is expected to be a significant turning point for the company, with the potential for breakeven driven by the continued growth of Carvykti sales and a clearer focus on in vivo CAR-T research [2][7]. - The current stock price reflects market expectations regarding the competitive landscape in the BCMA field, suggesting a high margin of safety [2]. - The target price has been adjusted to $60.40, down from $72.00, indicating a potential upside of 216.2% from the current price of $19.10 [1][8]. Financial Projections - Revenue projections for 2026 are estimated at $1,436 million, with a growth rate of approximately 50% expected [7][12]. - The gross profit for 2026 is projected to be $896 million, with a gross margin of 62.4% [6][12]. - The net profit for 2026 is forecasted to be $61 million, with a net profit margin of 4.3% [6][12]. Sales Performance - In Q4 2025, the company reported revenue of $283 million, a year-over-year increase of 52%, primarily driven by strong Carvykti sales [7]. - Carvykti sales in Q4 reached $555 million, with a year-over-year growth of 66% [7]. - The U.S. market saw a 38% year-over-year increase in sales, supported by an expanding treatment center network and increased patient penetration [7]. Market Position and Strategy - The management emphasizes the advantages of Carvykti over Tec-Dara in terms of administration convenience and patient survival benefits [7]. - The company plans to focus on expanding its market share in community treatment settings, where current penetration is only 5% among 2-4 line MM patients [7]. - Future catalysts include the CARTITUDE-5 study results expected by the end of 2026 or early 2027, and a shift in R&D focus towards in vivo CAR-T technologies [7].

Investment Rating - The report maintains a "Buy" rating for the company, Legend Biotech (LEGN US) [3][10]. Core Insights - The year 2026 is expected to be a significant turning point for the company, with financial stability anticipated as Carvykti sales continue to grow, potentially leading to breakeven [2][7]. - The focus of research and development is shifting towards in vivo CAR-T therapies, with early data expected within the year and potential business development opportunities [2][7]. - The current stock price reflects market expectations regarding competition in the BCMA field, indicating a high margin of safety for investors [2]. Financial Summary - Revenue projections for 2026 are estimated at $1.436 billion, with a gross profit of $896 million and a net profit of $61 million [6][12]. - The gross margin is projected to be 62.4% for 2026, with a net profit margin of 4.3% [6][12]. - The company's market capitalization is approximately $3.532 billion, with a 52-week high of $44.32 and a low of $16.65 [5][12]. Performance Indicators - The company achieved a quarterly revenue of $283 million in Q4 2025, marking a 52% year-over-year increase, driven by strong Carvykti sales [7]. - Carvykti's sales in the U.S. market for Q4 2025 grew by 38% year-over-year, with significant penetration into community treatment centers [7]. - The company plans to increase its production capacity to support an annual treatment demand of 20,000 doses [7]. Valuation - The discounted cash flow (DCF) target price for the company has been adjusted to $60.40, down from $72.00, reflecting changes in earnings forecasts for 2026 and 2027 [2][8]. - The potential upside from the current stock price to the target price is approximately 216.2% [11].